RECURSION PHARMACEUTICALS, INC. (RXRX) FY2025 10-K Annual Report
RECURSION PHARMACEUTICALS, INC. (RXRX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 25, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
RECURSION PHARMACEUTICALS, INC. FY2025 10-K Analysis
Business Overview
- • Core business: AI-native drug discovery platform integrating biology, chemistry, clinical development to accelerate novel medicine creation
- • New emphasis: Clinical validation of Recursion OS in 2025 with positive Phase 1b/2 data for REC-4881 in familial adenomatous polyposis (FAP)
Management Discussion & Analysis
- • Revenue $74.7M in 2025, up 27% YoY from $58.8M driven by Sanofi partnership; 2024 revenue rose 32% from $44.6M primarily from Roche partnership
- • Operating margin negative 868% (loss $648.1M on revenue $74.7M) worsening from 815% in 2024 (loss $479.0M on $58.8M revenue)
Risk Factors
- • FDA regulatory approval risk for all drug candidates currently in discovery or clinical stages, no products approved or commercial revenue as of 2026
- • Geopolitical risk from potential U.S. and foreign regulatory reviews on foreign investments, possibly limiting strategic alliances with international partners
RECURSION PHARMACEUTICALS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$75M
▲ +26.9% YoY
Net Income
-$645M
▼ -39.1% YoY
Operating Margin
-867.9%
▼ -5377bp YoY
Net Margin
-863.4%
▼ -7533bp YoY
ROE
-57.0%
▼ -1221bp YoY
Total Assets
$1.5B
▲ +1.8% YoY
EPS (Diluted)
$-1.44
▲ +14.8% YoY
Operating Cash Flow
-$372M
▼ -3.5% YoY
Source: XBRL data from RECURSION PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on RECURSION PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.